Testosterone has beneficial
effects on several cardiovascular risk factors, which include cholesterol, endothelial dysfunction and inflammation
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted th... - 0 views
Opioid growth factor improves clinical benefit and survival in patients with advanced p... - 0 views
Methionine enkephalin, its role in immunoregulation and cancer therapy - ScienceDirect - 0 views
1More
shared by Nathan Goodyear on 15 Aug 21
- No Cached
A novel mechanism of lung cancer inhibition by methionine enkephalin through remodeling... - 0 views
www.researchgate.net/..._of_the_tumor_microenvironment
M2 macrophages M1 macrophages cancer MET-enkephalins TME MET-5 tumor microenvironment
![](/images/link.gif)
-
MENK increased the infiltration of M1-type macrophages, natural killer cells, CD8+ T cells, CD4+ T cells, and dendritic cells into the TME, and decreased the proportion of myeloid inhibitory cells and M2-type macrophages. Plays particular role in preventing immune escape and immune dysfunction paramount to cancer metastasis
Killing effect of methionine enkephalin on melanoma in vivo and in vitro - 0 views
www.spandidos-publications.com/...or.2017.5918
MET-enkephalins tumor microenvironment cancer tumor TME MET-5 melanoma
![](/images/link.gif)
Losing Weight The Healthy Way - 1 views
1More
Gender differences in serum high-molecular-weight adiponectin levels in metabolic syndrome - 0 views
Highly Competent Dieticians - 1 views
1More
shared by Nathan Goodyear on 26 Feb 13
- No Cached
Testosterone: a metabolic hormone in health and disease - 0 views
joe.endocrinology-journals.org/...JOE-12-0455.full.pdf
low T low testosterone testosterone metabolic syndrome MetS hormone hormones men male health disease
![](/images/link.gif)
58More
shared by Nathan Goodyear on 13 May 13
- No Cached
Testosterone: a vascular hormone in health and disease - 0 views
joe.endocrinology-journals.org/...R47.full
testosterone hormone health disease hormones men male cardiovascular disease CVD
![](/images/link.gif)
-
In clinical studies, acute and chronic testosterone administration increases coronary artery diameter and flow, improves cardiac ischaemia and symptoms in men with chronic stable angina and reduces peripheral vascular resistance in chronic heart failure.
-
testosterone is an L-calcium channel blocker and induces potassium channel activation in vascular smooth muscle cells
- ...54 more annotations...
-
Animal studies have consistently demonstrated that testosterone is atheroprotective, whereas testosterone deficiency promotes the early stages of atherogenesis
-
there is no compelling evidence that testosterone replacement to levels within the normal healthy range contributes adversely to the pathogenesis of CVD (Carson & Rosano 2011) or prostate cancer (Morgentaler & Schulman 2009)
-
bidirectional effect between decreased testosterone concentrations and disease pathology exists as concomitant cardiovascular risk factors (including inflammation, obesity and insulin resistance) are known to reduce testosterone levels and that testosterone confers beneficial effects on these cardiovascular risk factors
-
Achieving a normal physiological testosterone concentration through the administration of testosterone replacement therapy (TRT) has been shown to improve risk factors for atherosclerosis including reducing central adiposity and insulin resistance and improving lipid profiles (in particular, lowering cholesterol), clotting and inflammatory profiles and vascular function
-
It is well known that impaired erectile function and CVD are closely related in that ED can be the first clinical manifestation of atherosclerosis often preceding a cardiovascular event by 3–5 years
-
no decrease in the response (i.e. no tachyphylaxis) of testosterone and that patient benefit persists in the long term.
-
free testosterone levels within the physiological range, has been shown to result in a marked increase in both flow- and nitroglycerin-mediated brachial artery vasodilation in men with CAD
-
Clinical studies, however, have revealed either small reductions of 2–3 mm in diastolic pressure or no significant effects when testosterone is replaced within normal physiological limits in humans
-
Endothelium-independent mechanisms of testosterone are considered to occur primarily via the inhibition of voltage-operated Ca2+ channels (VOCCs) and/or activation of K+ channels (KCs) on smooth muscle cells (SMCs)
-
Testosterone increases the expression of endothelial nitric oxide synthase (eNOS) and enhances nitric oxide (NO) production
-
In addition to direct effects on NOS expression, testosterone may also affect phosphodiesterase type 5 (PDE5 (PDE5A)) gene expression, an enzyme controlling the degradation of cGMP, which acts as a vasodilatory second messenger
-
the significance of the action of testosterone on VSMC apoptosis and proliferation in atherosclerosis is difficult to delineate and may be dependent upon the stage of plaque development
-
Several human studies have shown that carotid IMT (CIMT) and aortic calcification negatively correlate with serum testosterone
-
acute responses appear to be AR independent, long-term AR-mediated effects on the vasculature have also been described, primarily in the context of vascular tone regulation via the modulation of gene transcription
-
Several studies, however, have demonstrated that the vasodilatory actions of testosterone are not reduced by aromatase inhibition
-
non-aromatisable DHT elicited similar vasodilation to testosterone treatment in arterial smooth muscle
-
increased endothelial NOS (eNOS) expression and phosphorylation were observed in testosterone- and DHT-treated human umbilical vein endothelial cells
-
Androgen deprivation leads to a reduction in neuronal NOS expression associated with a decrease of intracavernosal pressure in penile arteries during erection, an effect that is promptly reversed by androgen replacement therapy
-
Observational evidence suggests that several pro-inflammatory cytokines (including interleukin 1β (IL1β), IL6, tumour necrosis factor α (TNFα), and highly sensitive CRP) and serum testosterone levels are inversely associated in patients with CAD, T2DM and/or hypogonadism
-
TRT has been reported to significantly reduce TNFα and elevate the circulating anti-inflammatory IL10 in hypogonadal men with CVD
-
testosterone treatment to normalise levels in hypogonadal men with the MetS resulted in a significant reduction in the circulating CRP, IL1β and TNFα, with a trend towards lower IL6 compared with placebo
-
Research suggests that the expression of VCAM-1, as induced by pro-inflammatory cytokines such as TNFα or interferon γ (IFNγ (IFNG)) in endothelial cells, can be attenuated by treatment with testosterone
-
Testosterone also inhibits the production of pro-inflammatory cytokines such as IL6, IL1β and TNFα in a range of cell types including human endothelial cells
-
decreased inflammatory response to TNFα and lipopolysaccharide (LPS) in human endothelial cells when treated with DHT
-
The key to unravelling the link between testosterone and its role in atherosclerosis may lay in the understanding of testosterone signalling and the cross-talk between receptors and intracellular events that result in pro- and/or anti-inflammatory actions in athero-sensitive cells.
-
Both NFκB and AR act at the transcriptional level and have been experimentally found to be antagonistic to each other
-
As the AR and NFκB are mutual antagonists, their interaction and influence on functions can be bidirectional, with inflammatory agents that activate NFκB interfering with normal androgen signalling as well as the AR interrupting NFκB inflammatory transcription
-
prolonged exposure of vascular cells to the inflammatory activation of NFκB associated with atherosclerosis may reduce or alter any potentially protective effects of testosterone
-
DHT and IFNγ also modulate each other's signalling through interaction at the transcriptional level, suggesting that androgens down-regulate IFN-induced genes
-
(Simoncini et al. 2000a,b). Norata et al. (2010) suggest that part of the testosterone-mediated atheroprotective effects could depend on ER activation mediated by the testosterone/DHT 3β-derivative, 3β-Adiol
-
TNFα-induced induction of ICAM-1, VCAM-1 and E-selectin as well as MCP1 and IL6 was significantly reduced by a pre-incubation with 3β-Adiol in HUVECs
-
3β-Adiol also reduced LPS-induced gene expression of IL6, TNFα, cyclooxygenase 2 (COX2 (PTGS2)), CD40, CX3CR1, plasminogen activator inhibitor-1, MMP9, resistin, pentraxin-3 and MCP1 in the monocytic cell line U937 (Norata et al. 2010)
-
This study suggests that testosterone metabolites, other than those generated through aromatisation, could exert anti-inflammatory effects that are mediated by ER activation.
-
The authors suggest that DHT differentially effects COX2 levels under physiological and pathophysiological conditions in human coronary artery smooth muscle cells and via AR-dependent and -independent mechanisms influenced by the physiological state of the cell
-
There are, however, a number of systematic meta-analyses of clinical trials of TRT that have not demonstrated an increased risk of adverse cardiovascular events or mortality
-
The TOM trial, which was designed to investigate the effect of TRT on frailty in elderly men, was terminated prematurely as a result of an increased incidence of cardiovascular-related events after 6 months in the treatment arm
-
trials of TRT in men with either chronic stable angina or chronic cardiac failure have also found no increase in either cardiovascular events or mortality in studies up to 12 months
-
Evidence may therefore suggest that low testosterone levels and testosterone levels above the normal range have an adverse effect on CVD, whereas testosterone levels titrated to within the mid- to upper-normal range have at least a neutral effect or, taking into account the knowledge of the beneficial effects of testosterone on a series of cardiovascular risk factors, there may possibly be a cardioprotective action
-
The effect of testosterone on human vascular function is a complex issue and may be dependent upon the underlying androgen and/or disease status.
-
the majority of studies suggest that testosterone may display both acute and chronic vasodilatory effects upon various vascular beds at both physiological and supraphysiological concentrations and via endothelium-dependent and -independent mechanisms
Highly Competent Dietitian - 1 views
19More
shared by Nathan Goodyear on 08 May 13
- No Cached
Beyond the male sex hormone: deciphering the metabolic and vascular actions of testoste... - 0 views
joe.endocrinology-journals.org/...C1.full
AR androgen receptors androgen receptor testosterone androgen receptors Diabetes metabolic syndrome MetS CVD cardiovascular disease men hormone hormones male
![](/images/link.gif)
-
androgen deprivation therapy results in unfavorable changes in body composition, insulin resistance, and dyslipidemia and predisposes men to develop atherosclerosis and an increased risk of cardiovascular mortality
-
The hypogonadal–obesity cycle hypothesis was originally proposed by Cohen in 1999 to explain the relationship between low testosterone levels and metabolic disease. It was based on the finding that obesity impairs testosterone levels by increasing the aromatization of testosterone to estradiol, while low testosterone levels promote increased fat deposition
-
adipocytokines contribute to low testosterone levels as well as to the processes underlying metabolic syndromes and type 2 diabetes
- ...15 more annotations...
-
The presence of estradiol and the adipocytokines TNF-α, IL6, and leptin (as a result of leptin resistance in obesity) inhibits the hypothalamic–pituitary–testicular axis response to decreasing androgen levels
-
An increasing number of studies have illustrated the potential for applying metabolomics to the field of androgen research
-
As early as the 1940s, the therapeutic use of testosterone was reported to improve angina pectoris in men with coronary artery disease
-
most of the epidemiological studies reported increased cardiovascular risk and mortality in men with low testosterone levels
-
long-term testosterone replacement appears to be a safe and effective means of treating hypogonadal elderly men
-
a recent interventional trial showed that testosterone treatment was associated with decreased mortality when compared with no testosterone treatment in an observational cohort of men with low testosterone levels
-
a number of short-term studies conducted support the notion that testosterone therapy reduces the cardiovascular risk
-
The majority of animal studies support the hypothesis that the actions of testosterone on vascular relaxation are both endothelium-dependent and -independent vasodilatory effects
-
Endothelial-dependent actions of testosterone increase the expression or activity of endothelial nitric oxide synthase and enhance nitric oxide production, which in turn activates cyclic guanosine monophosphate to induce vasorelaxation in smooth muscle cells
-
Endothelial-independent mechanisms of testosterone are believed to occur primarily via inhibition of voltage-operated Ca2+ channels and/or activation of K+ channels in smooth muscle cells
-
Testosterone may also inhibit intracellular Ca2+ influx via store-operated Ca2+ channels by blocking the response to prostaglandin F2α
-
testosterone has demonstrated anti-inflammatory effects to protect against atherogenesis in animal studies
-
both genomic AR activation to modulate gene transcription and non-genomic activation to modulate the rapid intracellular signaling pathways of ion channels may mediate testosterone effects on vascular function and inflammation.
-
Butenandt & Ruzicka first showed how testosterone is synthesized and responsible for masculine characteristics in the early 1930s
26More
shared by Nathan Goodyear on 11 Oct 12
- No Cached
ScienceDirect.com - Cell Metabolism - Estrogen Receptors and the Metabolic Network - 0 views
www.sciencedirect.com/...S1550413111003123
ER-alpha ER-beta estrogen receptor receptors metabolic syndrome MetS hormone hormones
![](/images/link.gif)
-
The pro-opiomelanocortin (POMC) neurons have an anorexigenic action and, when activated, reduce food intake through the release of two peptides, α-melanocyte-stimulating hormone (α-MSH) and cocaine-and-amphetamine-regulated transcripts (CART). The neuropeptide Y (NPY) neurons, on the other hand, release NPY hormone and agouti gene-related protein (AgRP), which prevent the binding of α-MSH to MC3R and MC4R, increasing food intake
-
The main hypothalamic areas involved in food intake and satiety are the arcuate nucleus (ARC), the lateral hypothalamus (LH), the paraventricular nucleus (PVN), the ventromedial hypothalamus (VMH), and the dorsomedial hypothalamus (DMH)
- ...22 more annotations...
-
Leptin is a potent anorexigenic and catabolic hormone secreted by adipose cells that reduces food intake and increases energy expenditure
-
E2 not only modulates leptin receptor mRNA in the ARC and VMH, but also increases hypothalamic sensitivity to leptin, altering peripheral fat distribution
-
ghrelin. It acts on growth hormone secretagogue receptors (GHSR1a) located in the ARC and is a potent stimulator of food intake
-
It thus appears that of the two ERs, ERα plays a predominant role in the CNS regulation of lipid and carbohydrate homeostasis.
-
Stimulation of MCH neurons increases food intake and fat accumulation while its inhibition leads to decreased food intake and reduced fat accumulation.
-
The PVN is the region of the hypothalamus with the highest expression of ERβ and is reported to be weakly ERα positive
-
GLUT4 is highly expressed in muscle and represents a rate-limiting step in the insulin-induced glucose uptake
-
data suggest that in the physiological range, E2 is beneficial for insulin sensitivity, whereas hypo- or hyperestrogenism is related to insulin resistance
-
In aging female rats, E2 treatment improves glucose homeostasis mainly through its ability to increase muscle GLUT4 content on the cell membrane
-
It is evident that ERα and ERβ have distinct actions and that much more research is needed to clearly identify the function of each receptor in muscle.
-
E2 prevents accumulation of visceral fat, increases central sensitivity to leptin, increases the expression of insulin receptors in adipocytes, and decreases the lipogenic activity of lipoprotein lipase in adipose tissue
-
In rats, ovariectomy increases body weight, intra-abdominal fat, fasting glucose and insulin levels, and insulin resistance followed by decreased phosphorylation of AMPK and its substrate acetyl-CoA carboxylase in adipose tissue
-
decreased adiponectin, PPARγ coactivator-1α (PGC-1α), and uncoupling protein 2 (UCP2) and increased resistin
-
Men with aromatase deficiency have truncal obesity, elevated blood lipids, and severe insulin resistance
-
Although not all studies are in agreement, polymorphisms of ERα in humans have been associated with risk factors for CVDs
-
Human subcutaneous and visceral adipose tissues express both ERα and ERβ, whereas only ERα mRNA has been identified in brown adipose tissue
-
very nice article that looks at the balance of ER-alpha/ER-beta and their role in metabolic syndrome. This article discusses the balance of these receptors are tissue dependent in their effect. I like their conclusion: "...but these mechanisms will never be completely understood if they are not considered in the context of a whole system.
1More
Estradiol and Metabolic Syndrome in Older Italian Men: The InCHIANTI Study -- Maggio et... - 0 views
1More
Prevalence of Sexual Dysfunction among Postmenopausal Women with and without Metabolic ... - 0 views
1More
shared by Nathan Goodyear on 30 Mar 12
- No Cached
The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome:... - 0 views
www.annals.org/...611.full
Lifestyle interventions metabolic syndrome MetS metformin diabetes prevention program
![](/images/link.gif)
1More
shared by Nathan Goodyear on 30 Mar 12
- No Cached
Clinical Importance of Obesity Versus the Metabolic Syndrome in Cardiovascular Risk in ... - 0 views
circ.ahajournals.org/...706.full
metabolic syndrome MetS weight-loss overweight obesity CVD cardiovascular disease
![](/images/link.gif)
15More
shared by Nathan Goodyear on 28 Aug 12
- No Cached
Redefining Metabolic Syndrome in Men (July 2012) Townsend Letter for Doctors & Patients - 0 views
www.townsendletter.com/...metsyndrome0712.html
testosterone male men hormone hormones saliva salivary low T low metabolic syndrome MetS
![](/images/link.gif)
-
Approximately 95% to 98% of testosterone is bound to a carrier protein at any given time, leaving just the remaining 2% to 5% as completely unbound and available for tissues to use
-
most serum laboratories offer a free testosterone level, which is a calculated value based on SHBG levels or determined with equilibrium dialysis
- ...11 more annotations...
-
Testosterone has a known age-related decline, and total levels typically drop by approximately 1.6% per year beginning for most men in their 30s
-
As estrogen levels rise, they prompt the body to produce more SHBG, which in turn has a higher binding affinity for testosterone, and drives the unbound fraction of the testosterone pool down even further
-
When the increase in SHBG is taken into account, the age-related decline in the level of hormone that can be used by the body is closer to 2% to 3% per year.
-
Stinging nettle (Urtica dioica), an herb commonly used for allergies, can also be employed to bind to SHBG, which leaves more testosterone available to tissues
-
Leptin, an adipose-derived peptide hormone that regulates appetite and metabolism, has been shown to directly inhibit testosterone production in animal models
-
tumor necrosis factor alpha (TNF-alpha) and interleukin-1 (IL-1) further inhibit Leydig cell testosterone production
-
there are several herbs that can work to boost testosterone levels, including longjack (Eurycoma longifolia), horny goat weed (Epimedium grandiflorum), and tribulus (Tribulus terrestris).
-
the majority of the hormone is bound to carrier proteins including sex hormone binding globulin (SHBG) and albumin